AMG
TXMD icon

Asset Management Group’s TherapeuticsMD TXMD Stock Holding History

Asset Management Group’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,701
Closed -$98K – 123
2022
Q3 		$98K Hold
14,701
– – 0.02% 118
2022
Q2 		$146K Hold
14,701
– – 0.04% 120
2022
Q1 		$279K Sell
14,701
-454
-3% -$7.14K 0.06% 111
2021
Q4 		$269K Buy
15,155
+14,312
+1,698% +$429K 0.05% 112
2021
Q3 		$31K Hold
843
– – 0.01% 127
2021
Q2 		$50K Buy
+843
New +$51.1K 0.01% 129

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Asset Management Group's TXMD Position: Q4 2022 in Review

Asset Management Group sold out of TherapeuticsMD (TXMD) in Q4 2022, closing a stake of 14,701 shares — an estimated $98K sold.

Asset Management Group first reported a position in TXMD in Q2 2021 and held it in 6 quarters. The position peaked at $279K in Q1 2022. 44 funds tracked by Wall St. Rank hold TXMD as of Q4 2022.

  • Asset Management Group reported no remaining TherapeuticsMD position as of Q4 2022 after selling out during the quarter.
  • Asset Management Group sold 14,701 TherapeuticsMD shares in Q4 2022, an estimated $98K.
  • Asset Management Group first reported a position in TherapeuticsMD in Q2 2021 and held it in 6 quarters.
  • Asset Management Group's TherapeuticsMD position peaked at $279K in Q1 2022.
  • 44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2022.

Based on Asset Management Group's 13F filing for Q4 2022, filed 14 Feb 2023.